fine revenu guidanc reiter ep guidanc increas due
tax reform importantli key pillar outperform thesi remain intact core
busi sustain msd growth cyno appear stabil tax reform
boost eps/cash flow valuat remain favor even attract
rel basi
revenu report organ exclud fx blood cynosur
adjust day ahead consensu ahead forecast
howev adjust blood screen revenu line forecast
report basi organ revenu close adjust day
forecast larg due diagnost breast health upsid importantli mdx revenu
cc close exclud fewer sell day headwind continu
grow solid clip howev novasur revenu y/i continu
under-perform expect full revenu detail page
gross margin y/i line forecast
consensu oper margin y/i forecast
consensu ep y/i beat consensu forecast
rel forecast beat entir due lower expect tax rate
adjust favor tax rate share count ep line forecast
full year report revenu guidanc reiter
constant currenc growth guidanc slightli decreas
manag indic done entir maintain absolut revenu
guidanc rang essenti organ revenu growth guidanc msd remain unchang
full year ep increas entir due
lower tax rate vs previous increas ep guidanc reflect
half tax save half expect reinvest
 revenu guid consensu ep
consensu prior consensu revenu estim appear accur
importantli key pillar outperform thesi remain intact core busi
sustain msd level growth cyno appear stabil tax reform
boost eps/cash flow valuat remain favor valuat note
trade calendar year ep calendar year ep
repres discount rel med-tech peer group
discount rel continu view risk/reward attract current
pleas see page report import disclosur
believ posit sustain msd level core revenu growth
next sever year combin point tax rate cut opportun capit
deploy drive robust ep growth exce expect
discount peer yield risk/reward favor
tax rate trend downward remain
us tax reform drive tax rate low
high
cynosur growth return
ep growth
cynosur outperform expect
return growth
ep growth
ep growth
develop manufactur supplier premium diagnost medic imag
system surgic product dedic healthcar need women compani
core busi segment focus breast health diagnost gyn surgic
skelet health august acquir gen-prob global leader
develop manufactur market rapid accur cost-effect molecular
diagnost product servic use primarili diagnos human diseas
compani report thomson eikon cowen compani
cowen vs consensu mm except cc msd organ cc gross expect expans base expect expans base om expand faster ep revenu metric mm except statement mm except line forecast pre-tax per count lower expect share count contribut ep tax rate forecast contribut ep ep y/i beat consensu forecast rel forecast beat entir due lower expect tax rate adjust favor tax rate share count ep line health beat forecast larg intervent breast solut upsid skelet forecast novasur key driver miss rel forecast myosur forecast continu grow rate full year revenu organ exclud fx blood cynosur adjust day ahead consensu ahead forecast howev adjust blood screen revenu line forecast report basi organ revenu close adjust day forecast larg due diagnost breast health upsid gross margin y/i line forecast consensu expens forecast sg expens forecast oper margin y/i forecast diagnost revenu beat forecast beat driven blood screen even adjust blood screen solid beat mdx organ revenu growth approxim adjust fewer sell day cynosur revenu forecast seemingli line street expect cowen
compani report thomson eikon cowen compani
cagrcommentstot cc msd organ fx msd growth excl blood re-affirmed molecular like contribut annual mdx revenueblood blood us mixbreast growth like better initi lsd guidancebreast imag incl breast lsd growth revenu sequenti revenu sequenti lowerreport excl blood grth excl blood breast normal deal excl blood breast excl blood royalti cyno cowen
compani report thomson eikon cowen compani
except per share cc msd organ fx cc compar organ expect expans base blood screen headwind fy gross increment d/sg spend due tax save gener increment d/sg spend due tax save oper increment d/sg spend due tax save non-oper interest net non-oper expens materi higher y/yearn tax rate earn per ep share count except per share gross op consensu cowen
price target base sever methodolog may includ analysi market risk
group ev/ebitda premium discount averag group price-to-earnings sum part net asset
valu dividend return return equiti roe next month
risk medic life scienc tool sector may includ reduct delay research
develop budget govern fund reduc delay purchas
health care hospit custom increas extend regulatori hurdl process
regul product increas depend volatil emerg market revenu
profit gener macroeconom challeng
make invest recommend earli stage pre-commerci ls dt
compani base upon assess technolog probabl market success
competit regulatori reimburs etc potenti market opportun
event success howev compani lack tradit and/or matur
financi metric believ good methodolog assign specif
target price stock
risk downsid includ limit cynosur much wors
current model headwind growth novasur pap test
reform stall dc enter agreement larg refer
laboratori maintain busi import mdx franchis
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock thermo fisher scientif secur
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
